shutterstock_1862407378_ralf_liebhold

Ralf Liebhold / Shutterstock.com

17 November 2022Big PharmaStaff Writer

Teva secures victory in iron overload treatment dispute

Judge Hacon rules that a skilled team “would have thought it obvious” to reformulate drug into a tablet | Teva DFX patents also found not to infringe, falling outside the claims on both a normal construction and under the doctrine of equivalents.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Otsuka says Teva’s REXULTI generic infringes patents

24 February 2022 Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.

Teva breached antitrust rules over Copaxone, says EU

11 October 2022 European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.

More on this story

Otsuka says Teva’s REXULTI generic infringes patents

24 February 2022 Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.

Teva breached antitrust rules over Copaxone, says EU

11 October 2022 European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.

More on this story

Otsuka says Teva’s REXULTI generic infringes patents

24 February 2022 Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.

Teva breached antitrust rules over Copaxone, says EU

11 October 2022 European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.

More features

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court

Cooley adds ex-Gowling partner